Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study

for
Tumor
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05879146

Phase 2, Recruiting

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

for
Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch,
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: Female

Age: 18+

Code: NCT05979610

Phase 2, Recruiting

Ovarian Tissue Cryopreservation in Pre-Pubertal (OTC-Pre Pubertal)

for
Cancers
Location: Chicago IL
Sponsor: Erin Rowell

Sex: Female

Age: 0 - 11

Code: NCT05299710

Recruiting

SW-682 in Advanced Solid Tumors

for
Advanced Solid Tumor, Mesothelioma, Malignant
Location: Cleveland OH, Houston TX, Dallas TX, Scottsdale AZ,
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Sex: All

Age: 18+

Code: NCT06251310

Phase 1, Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

for
Solid Tumors With HRAS Alterations,
Location: Boston MA, New Brunswick NJ, Pittsburgh PA,
Sponsor: Kura Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06026410

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

for
Solid Tumor
Location: Houston TX, Gilbert AZ
Sponsor: Virogin Biotech Canada Ltd

Sex: All

Age: 18+

Code: NCT05266612

Phase 1, Recruiting

Evidence Development in Cancer Treatment - Real World: PREDiCTrw

for
Cancer
Location: Vancouver
Sponsor: British Columbia Cancer Agency

Sex: All

Age: 18+

Code: NCT06242912

Recruiting

A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

for
Solid Tumor, Adult, Lymphoma
Location: Houston TX, Duarte CA
Sponsor: Cyclacel Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT04983810

Phase 1, Phase 2, Recruiting

TREC@TAMU Cancer Prevention Registry and Repository

for
Cancer, Genetics, Disease, Diet, Lifestyle Factors
Location: Bryan TX
Sponsor: Texas A&M University

Sex: All

Age: 18+

Code: NCT06826014

Recruiting

Ovarian Tissue Cryopreservation for Fertility Preservation

for
Cancer, Autoimmune Diseases
Location: Pittsburgh PA
Sponsor: University of Pittsburgh

Sex: Female

Age: 0 - 39

Code: NCT05875155

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

for
Tumor, Subjects
Location: San Antonio TX
Sponsor: Huabo Biopharm Co., Ltd.

Sex: All

Age: 18+

Code: NCT04678908

Phase 1, Recruiting

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

for
Advanced Solid Tumors
Location: Miami Beach FL, St. Petersburg FL, New Orleans LA
Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Sex: All

Age: 18+

Code: NCT05277168

Phase 1, Phase 2, Recruiting

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

for
Breast Cancer, Oligoprogressive, Head and Neck Cancer, Sarcoma,
Location: Sacramento CA
Sponsor: University of California, Davis

Sex: All

Age: 18+

Code: NCT06103669

Recruiting

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

for
Malignant Head and Neck Neoplasm, Malignant Neoplasm,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT01365169

Recruiting

eSense-Cancer: Adapting an Online Intervention for Sexual Health Concerns to Gynecologic Cancer

for
Gynecologic Cancers
Location: Vancouver
Sponsor: University of British Columbia

Sex: Female

Age: 19+

Code: NCT06619769

Recruiting

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

for
Cancer Diagnosis
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 45+

Code: NCT06523868

Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

for
Advanced/Metastatic Solid Tumors, Colorectal Cancer,
Location: Boston MA, New York NY, Philadelphia PA, Syracuse NY,
Sponsor: Genmab

Sex: All

Age: 18+

Code: NCT03526835

Phase 1, Phase 2, Recruiting

Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Nashville TN
Sponsor: MetaboMed Inc

Sex: All

Age: 18+

Code: NCT04990739

Phase 1, Recruiting

Prospective Urban Rural Epidemiology Study

for
Cardiovascular Diseases, Risk Factor, Cardiovascular,
Location: Quebec City, Ottawa, Hamilton, Vancouver
Sponsor: Population Health Research Institute

Sex: All

Age: 35 - 70

Code: NCT03225586

Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumors, HNSCC, SCLC, NSCLC,
Location: Boston MA, New York NY, New Haven CT, Miami FL, Toronto,
Sponsor: Tubulis GmbH

Sex: All

Age: 18+

Code: NCT06657222

Phase 1, Phase 2, Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial